The Worst Mistake Pfizer Investors Can Make in 2022
It's been a great year for Pfizer (NYSE: PFE) and its investors as the company's share price is up more than 62% this year. Also, Pfizer has said it expects to record annual revenue of between $81 billion and $82 billion, which would mean growth of between 93% and 95%, year over year. Pfizer added that full-year adjusted diluted earnings per share (EPS) are expected to be between $4.13 to $4.18, up 142% to 144% compared to full-year 2020 EPS. The company appears to be on track to meet those targets. Through nine months, the company reported revenue of $57.6 billion, up 91% year over year, and adjusted diluted EPS of $3.27, up 82% over the same period last year.
Much of that rise has been due to Comirnaty, the COVID-19 vaccine the company developed with BioNTech. Pfizer, in its third-quarter report, said it will make $36 billion in revenue from the vaccine this year. It's easy to look at those numbers and think the stock's price is high and this might be as good as it gets, and cash out. That would be the worst mistake Pfizer investors could make next year.
Is the company likely to have the type of growth next year that it had this year? No, probably not. However, as we are beginning to see, COVID-19 is not going away anytime soon. And besides that, Pfizer is hardly a one-trick pharmaceutical giant.
Source Fool.com
